• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hemolytic anemia following alectinib reported to the U.S. Food and Drug Administration Adverse Event Reporting System.

作者信息

Dores Graça M, Nayernama Afrouz, Cheng Connie, Moureaud Charlotte, Jones S Christopher

机构信息

Division of Pharmacovigilance, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

出版信息

Am J Hematol. 2022 Apr;97(4):E129-E132. doi: 10.1002/ajh.26454. Epub 2022 Jan 19.

DOI:10.1002/ajh.26454
PMID:34985778
Abstract
摘要

相似文献

1
Hemolytic anemia following alectinib reported to the U.S. Food and Drug Administration Adverse Event Reporting System.阿来替尼治疗后发生的溶血性贫血已报告给美国食品药品监督管理局不良事件报告系统。
Am J Hematol. 2022 Apr;97(4):E129-E132. doi: 10.1002/ajh.26454. Epub 2022 Jan 19.
2
Alectinib-induced Hemolytic Anemia with Positive Direct Antiglobulin Test in a Patient with Lung Adenocarcinoma: A Possible Drug-drug Interaction Effect.一例肺腺癌患者使用阿来替尼后出现直接抗人球蛋白试验阳性的溶血性贫血：一种可能的药物相互作用效应
Intern Med. 2024 Mar 1;63(5):711-715. doi: 10.2169/internalmedicine.1286-22. Epub 2023 Jul 12.
3
Ibrutinib-related skin cancer: A pharmacovigilance study from the Food and Drug Administration Adverse Event Reporting System.依鲁替尼相关皮肤癌：一项来自美国食品药品监督管理局不良事件报告系统的药物警戒研究。
Eur J Cancer. 2022 Jan;160:277-278. doi: 10.1016/j.ejca.2021.10.034. Epub 2021 Dec 2.
4
Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.氨磺必利的新型不良事件：美国食品药品监督管理局不良事件报告系统（FAERS）数据库中的不成比例性分析。
Curr Drug Saf. 2019;14(1):21-26. doi: 10.2174/1574886313666181026100000.
5
[Analysis of Information on Drug Adverse Reactions Using U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)].[使用美国食品药品监督管理局不良事件报告系统（FAERS）对药物不良反应信息进行分析]
Yakugaku Zasshi. 2022;142(4):341-344. doi: 10.1248/yakushi.21-00178-5.
6
FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib.FDA 批准：阿来替尼用于克唑替尼治疗后进展的、ALK 阳性的转移性非小细胞肺癌。
Clin Cancer Res. 2016 Nov 1;22(21):5171-5176. doi: 10.1158/1078-0432.CCR-16-1293. Epub 2016 Jul 13.
7
Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.药物相关性急性肾损伤在美国食品和药物管理局不良事件报告系统数据库中的识别。
Pharmacotherapy. 2018 Aug;38(8):785-793. doi: 10.1002/phar.2152. Epub 2018 Jul 13.
8
[Analysis of Time-to-onset of Interstitial Lung Disease after the Administration of Small Molecule Molecularly-targeted Drugs].小分子分子靶向药物给药后间质性肺疾病发病时间分析
Yakugaku Zasshi. 2018;138(2):229-235. doi: 10.1248/yakushi.17-00194.
9
Does HIF-PHI increased risk of gastrointestinal hemorrhage in patients with renal anemia: a review of cases reported to the U.S. Food and drug administration adverse event reporting system.缺氧诱导因子脯氨酰羟化酶抑制剂（HIF-PHI）会增加肾性贫血患者胃肠道出血的风险吗：对向美国食品药品监督管理局不良事件报告系统报告的病例的回顾
Ren Fail. 2021 Dec;43(1):1170-1171. doi: 10.1080/0886022X.2021.1952881.
10
Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration.利用自愿提交给美国食品药品监督管理局的上市后不良事件报告对韦伯效应进行复制。
Pharmacotherapy. 2004 Jun;24(6):743-9. doi: 10.1592/phco.24.8.743.36068.

引用本文的文献

1
Lorlatinib overcomes alectinib-induced hemolytic anemia in an ALK fusion positive non-small-cell lung cancer patient with severe tumor-associated liver failure: A case report.劳拉替尼在一名伴有严重肿瘤相关性肝衰竭的ALK融合阳性非小细胞肺癌患者中克服了阿来替尼诱导的溶血性贫血：一例报告
Thorac Cancer. 2024 Dec;15(36):2570-2574. doi: 10.1111/1759-7714.15487. Epub 2024 Nov 11.
2
Alectinib-induced Hemolytic Anemia with Positive Direct Antiglobulin Test in a Patient with Lung Adenocarcinoma: A Possible Drug-drug Interaction Effect.一例肺腺癌患者使用阿来替尼后出现直接抗人球蛋白试验阳性的溶血性贫血：一种可能的药物相互作用效应
Intern Med. 2024 Mar 1;63(5):711-715. doi: 10.2169/internalmedicine.1286-22. Epub 2023 Jul 12.
3
Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors.
间变性淋巴瘤激酶酪氨酸激酶抑制剂不良反应管理的专家共识。
ESMO Open. 2023 Jun;8(3):101560. doi: 10.1016/j.esmoop.2023.101560. Epub 2023 May 23.
4
Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report.阿来替尼致ALK阳性非小细胞肺癌患者严重溶血性贫血：一例报告
Onco Targets Ther. 2023 Jan 24;16:65-69. doi: 10.2147/OTT.S398375. eCollection 2023.
5
Successful Treatment with Brigatinib after Alectinib-Induced Hemolytic Anemia in Patients with Metastatic Lung Adenocarcinoma-A Case Series.布加替尼治疗阿来替尼诱导的转移性肺腺癌患者溶血性贫血的成功案例系列。
Curr Oncol. 2022 Dec 30;30(1):518-528. doi: 10.3390/curroncol30010041.